Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258089 | 0.91 | CYP1A2 (0.60) | CYP1A2PPARGHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3657063 | 0.86 | HTT (0.56) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3656048 | 0.85 | HTT (0.59) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL9733037 | 0.83 | KMT2A (0.48) | CYP1A2PPARGHTTSMN1; SMN2MEN1 | |
| SCHEMBL12926735 | 0.81 | CYP1A2 (0.49) | CYP1A2PPARGHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12926710 | 0.78 | CYP1A2 (0.43) | CYP1A2PPARGHTTSMN1; SMN2MEN1 | |
| SCHEMBL3660873 | 0.78 | CYP1A2 (0.49) | CYP1A2PPARGHTTSMN1; SMN2MEN1 | |
| SCHEMBL12926793 | 0.77 | CYP1A2 (0.46) | CYP1A2PPARGHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3657694 | 0.77 | HTT (0.59) | CYP1A2HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL9457070 | 0.76 | PPARG (0.58) | CYP1A2PPARGHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364424-B2 | Topical cosmetic skin lightening compositions and methods of use thereof | STIEFEL LABORATORIES, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160074315-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. | 2016-03-17 | — | — | US | disclosed |
| EP-2219600-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009067095-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | CYP1A2 4758/4885PPARG 1178/4885HTT 22/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | CYP1A2 3751/4885PPARG 1824/4885HTT 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.